Cold Agglutinin Disease (CAD) is a condition where the immune system attacks and destroys red blood cells, especially when it's cold. This study is looking to collect real-world data from people with CAD or Cold Agglutinin Syndrome (CAS). The registry will observe patients over time to understand their condition better. Some patients will have been treated with a medication called sutimlimab in prior studies and will continue in this study.
To join, you must be at least 18 years old, diagnosed with CAD or CAS, and have given permission for your health information to be used in the study. You cannot join if you have another type of anemia or are currently in another CAD or CAS study.
- This study is observational, meaning no new treatment is given, just data collection.
- Participants can be from different countries and will be observed over time.
- No specific risks mentioned, but participants should have completed other related studies.
How understandable was the trial content above?
Hard to understand
Easy to understand